豪威集团(603501)
OmniVision reported 1H25 results. 1H revenue rose 15% YoY to RMB14.0bn,led by double-digit growth in Analog Solutions (+21% YoY) and Distribution(+42% YoY). During the period, gross margin remained stable at 30.5% (+1.3 pptsYoY), while net profit surged by 48% YoY to RMB2.0bn. NPM improved to 14.5%(from 11.3% in 1H24), reflecting operating leverage and cost control. The salesof OV’s core business, CIS, reached a record RMB10.3bn (+11% YoY), with auto,security, emerging IoT, and medical CIS growing 30%, 17%, 249%, and 68%YoY, respectively, offsetting weakness in mobile CIS (-19% YoY). We believeOmniVision is well-positioned in the CIS market, with leading market share in autoCIS, medical CIS, etc. We forecast its revenue to grow at 18%/25% YoY in2025/26E, while NP to increase by 24%/50% YoY. Maintain BUY with TP ofRMB173.
Auto CIS remained a key growth pillar, accounting for 37% of segmentsales with revenue of RMB3.8bn (+30% YoY). The growth was fueled byADAS penetration and cabin imaging demand. With a ~30% global marketshare (per TechInsights) and tailwinds from China’s “intelligent drivingequality” policy, we expect OV’s auto CIS sales to grow at 40% YoY in both2025E and 2026E.
Mobile CIS faced headwinds in 1H (-19% YoY) due to cyclical demandtransition (end-of-cycle demand for OV50H EOL) and slow smartphonerecovery in China (domestic shipment grew 3.3% YoY in 1Q25 ongovernment subsidies but decreased 4%/4% YoY/QoQ in 2Q as demand fell).We expect a seasonal pickup in 2H, but project full-year mobile CISrevenue to decline 15% YoY as the headwinds persist (2025 smartphoneshipment to grow by a merely 0.6%/1.9% YoY, per IDC/Counterpoint).Growth should resume in 2026E with design-wins in 200MP sensors andnew product cycles.
Emerging IoT and Medical CIS showed explosive growth, while securitydemand gradually recovers. Emerging IoT revenue surged by 249% YoYto RMB1.2bn in 1H25, driven by sports cameras, XR, and machine vision.Medical CIS rose 68% YoY to RMB443mn. Security CIS grew by 17% YoY toRMB827mn, due to rising adoption of its high-end products (Nyxel tech) andmarket recovery. We expect Emerging IoT and Medical CIS to maintainsignificant growth at 230%/50% YoY in 2025E.
Maintain BUY with TP of RMB173, based on 33.6x 2026E P/E (in-line withhistorical 2-year average). Previous TP was RMB176 (41x 2025E P/E). Wecut 2025/26E net profit forecasts by 19%/15% on slower mobile CIS rampand GPM headwinds from mix shift (greater distribution sales contribution).We remain optimistic on OV with 50% YoY profit growth projection for 2026E,considering new mobile CIS product ramp-up and margin improvement. Keyrisks: Soft smartphone shipments and intensified competition.